pxd fda s3 news must be close, page-7

Hi Moosey, yeah some interesting price action. Good news for shareholders in NRT is that they are focusing all activities on OVATURE. If they lacked the faith they would dump the trial and/or concentrate on other activities.

If the price falls significantly (20c or below) I'll sell some other shares have average down. But the trouble is everything else in the market is cheap and there looks to be little development in NRT for at least 6 months (unless of course the IDMC cut the trial early due to excellent results). Just a waiting game till full recruitment, should have the 95 events by now... just need the 340 enrolled patients.